TNGX
Tango Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$21.74
−7.45%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$23.33
From 52W high−33.92%
Volume6.16M
Market cap$3.67B
P/E (TTM)—
P/S (TTM)68.1x
Div yield—
Key dataSep 18, 2026
Open
$23.33
From 52W high
−33.92%
Volume
6.16M
Market cap
$3.67B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−21.9x
P/E (TTM)
—
RSI (14)
37.5
MomentumView details →
1D Return
−7.45%
YTD Return
+148.76%
SummaryUpdated Jun 1, 2026
Tango Therapeutics, Inc. (NASDAQ:TNGX) is a biotechnology company founded in 2017 and headquartered in Cambridge, Massachusetts. The company went public in September 2020 through a special purpose acquisition company (SPAC) merger. Tango focuses on discovering and developing targeted cancer therapies using a precision medicine approach called synthetic lethality, where drugs are designed to selectively kill cancer cells with specific genetic vulnerabilities while sparing healthy cells.
Similar companies
Latest newsMore news →
Tango Therapeutics reported Q2 2026 financial results with zero revenue, a net loss of $55.3 million, and diluted EPS of -$0.37, while highlighting a 92% objective response rate for vopimetostat plus daraxonrasib and a 90% six-month progression-free survival rate.41d agoTango Therapeutics announced that Executive Chairman Dr. Barbara Weber will step down in connection with other pursuits.45d ago